Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Büşra Gürel"'
Autor:
Büşra Gürel Günenç
Publikováno v:
Artuklu Akademi, Vol 5, Iss 2, Pp 419-424 (2018)
Mahmut Aydın, tanıtmaya çalıştığımız eserinde genel olarak Hz. İsa'nın başına gelen olaylar silsilesini, özelde ise çarmıh hadisesi ve sonrasını ele almaktadır. Tarihi kaynaklarda, Hristiyan dini kaynaklarda ve Kur'an-ı Kerim'de v
Externí odkaz:
https://doaj.org/article/d6452bf479724188bc120986d69d238b
Autor:
Büşra Gürel, Eda Çapkın, Ayhan Parlar, Aylin Özkan, Meltem Çorbacıoğlu, Duygu Emine Dağlikoca, Meral Yüce
Publikováno v:
Scientia Pharmaceutica, Vol 90, Iss 2, p 36 (2022)
Bevacizumab is a humanized therapeutic monoclonal antibody used to reduce angiogenesis, a hallmark of cancer, by binding to VEGF-A. Many pharmaceutical companies have developed biosimilars of Bevacizumab in the last decade. The official reports provi
Externí odkaz:
https://doaj.org/article/a00f14c450b247d2a048b9f417756e39
Autor:
Sabiha Aydoğdu, Djursun Karasartova, Ünsal Savcı, Ayşe Semra Güreser, Gönül Arslan Akveran, Merve Aktı, Büşra Gürel, Çağdaş Kocaman, Aytaç Acar, Nezahat Koşar, Lihua Xiao, Ayşegül Taylan Özkan
Publikováno v:
Flora the Journal of Infectious Diseases and Clinical Microbiology. 26:620-627
Autor:
GÜNENÇ, Büşra Gürel
Mahmut Aydın, tanıtmaya çalıştığımız eserinde genel olarak Hz. İsa'nın başına gelen olaylar silsilesini, özelde ise çarmıh hadisesi ve sonrasını ele almaktadır. Tarihi kaynaklarda, Hristiyan dini kaynaklarda ve Kur'an-ı Kerim'de v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4865::743f91f6e0dc09e011fde740eb00fac6
https://hdl.handle.net/20.500.12514/2453
https://hdl.handle.net/20.500.12514/2453
Publikováno v:
Scientia Pharmaceutica, Vol 91, Iss 3, p 31 (2023)
Alterations in the biological activity of the molecules under stress conditions have not been documented as widely in the literature yet. This study was designed to reveal the functional impacts of various oxidation conditions on a model mAb, a comme
Externí odkaz:
https://doaj.org/article/52f4e920895f4a83ba61c186d14d99bf
Autor:
Busra Gurel, Melike Berksoz, Eda Capkin, Ayhan Parlar, Meltem Corbacioglu Pala, Aylin Ozkan, Yılmaz Capan, Duygu Emine Daglikoca, Meral Yuce
Publikováno v:
Pharmaceutics, Vol 14, Iss 8, p 1571 (2022)
Avastin® is a humanized recombinant monoclonal antibody used to treat cancer by targeting VEGF-A to inhibit angiogenesis. SIMAB054, an Avastin® biosimilar candidate developed in this study, showed a different charge variant profile than its innovat
Externí odkaz:
https://doaj.org/article/d639b8ba82f649c6b9f86058a8458ef5